Researcher
Steven De Jonghe
- Disciplines:Microbiology, Systems biology, Laboratory medicine
Affiliations
- Laboratory of Virology and Chemotherapy (Rega Institute) (Division)
Member
From1 May 2017 → Today - Medicinal Chemistry (Rega Institute) (Division)
Member
From18 Feb 2002 → 30 Apr 2017
Projects
1 - 10 of 18
- Synthesis of agonists for the C-C chemokine receptor type 5 (CCR5), derived from a substituted 4-aminopiperidinyl lead structureFrom1 Jan 2023 → TodayFunding: BOF - doctoral mandates
- Optimisation of a triterpene lead compound for the development of pan-anticoronavirus drugs targeting nsp15From3 Jan 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Synthesis and structure-activity relationship studies of CCR8 agonists as a novel treatment option for autoimmune diseasesFrom27 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The synthesis of novel CXCR4 antagonists for use in oncology and molecular imagingFrom1 Oct 2020 → 30 Sep 2021Funding: BOF - postdoctoral mandates
- An NMR facility tailored for biomedical researchFrom1 May 2020 → TodayFunding: FWO Medium Size Research Infrastructure
- Synthesis of nucleoside analogues as antiviral and antibacterial agentsFrom10 Feb 2020 → 10 Feb 2024Funding: Own budget, for example: patrimony, inscription fees, gifts
- Development and application of NanoBRET-based technology: Unravelling signalling bias at the human chemokine receptors CXCR1 and CXCR2From3 Sep 2019 → 3 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Synthesis of CXCR2 and CCR7 chemokine receptor antagonists targeting a conserved intracellular binding siteFrom3 Oct 2018 → 10 Jan 2023Funding: BOF - doctoral mandates
- Establishment of in vitro assays for the discovery of GPCR small molecule ligandsFrom30 May 2018 → 30 May 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- IN SEARCH FOR SUGAR, BASE OR PHOSPHATE MODIFIED NUCLEOSIDES ACTIVE AGAINST RNA VIRUSESFrom30 Nov 2017 → 7 Mar 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
41 - 50 of 129
- IN SEARCH FOR SUGAR, BASE OR PHOSPHATE MODIFIED NUCLEOSIDES ACTIVE AGAINST RNA VIRUSES(2022)
Authors: Zihua Zheng, Graciela Andrei, Elisabetta Groaz, Steven De Jonghe, Piet Herdewyn
- An Overview of Marketed Nucleoside and Nucleotide Analogs.(2022)
Authors: Steven De Jonghe, Piet Herdewyn
Pages: e376 - Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses(2022)
Authors: Laura Vangeel, Steven De Jonghe, Dirk Jochmans, Johan Neyts
Pages: 2905 - 2920 - The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern(2022)
Authors: Rana Abdelnabi, Dirk Jochmans, Laura Vangeel, Steven De Jonghe, Patrick Augustijns, Birgit Weynand, Johan Neyts
- Synthesis, Structure-Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication(2022)
Authors: Laura Vangeel, Erion Lyoo, Eveline Lescrinier, Pieter Leyssen, Dirk Jochmans, Johan Neyts, Steven De Jonghe
- Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern(2022)
Authors: Laura Vangeel, Steven De Jonghe, Piet Maes, Emmanuel Andre, Pieter Leyssen, Johan Neyts, Dirk Jochmans
- Exploring the dNTP -binding site of HIV-1 reverse transcriptase for inhibitor design(2021)
Authors: Weijie Gu, Sergio Martinez, Abhi Singh, Jef Rozenski, Dominique Schols, Piet Herdewyn, Kalyan Das, Steven De Jonghe
- Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells(2021)
Authors: Rui Wang, Haibo Hu, Dirk Daelemans, Steven De Jonghe, Walter Luyten, Wim Dehaen
- Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease(2021)
Authors: Steven De Jonghe, Dirk Daelemans
- 1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors(2021)
Authors: Dirk Jochmans, Steven De Jonghe, Johan Neyts
Patents
1 - 10 of 10
- Isoquinoline and pyridine based cxcr4 antagonists (Inventor)
- Prodrugs of nucleoside phosphonates (Inventor)
- Novel prodrugs of nucleoside phosphonates (Inventor)
- Prodrugs of fluorinated acyclic nucleoside phosphonates (Inventor)
- Antiviral activity of bicyclic heterocycles (Inventor)
- Antiviral compounds, a process for their preparation, and their use for treating viral infections (Inventor)
- Prodrugs of fluorinated acyclic nucleoside phosphonates (Inventor)
- Purine analogues and their use as immunosuppressive agents (Inventor)
- Novel prodrugs of nucleoside phosphonates (Inventor)
- Gak modulators as antivirals (Inventor)